SML3625

BAY-069

≥98% (HPLC)

• Synonym(e): 3-(4-Chloro-3-(o-tolyloxy)naphthalen-1-yl)-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione, 3-(5-chloro-4-(2-methyl-phenoxy)-bicyclo[4.4.0]deca-1(6),2,4,7,9-pentaen-2-yl)-6-(trifluoro-methyl)-1,2,3,4-tetrahydro-pyrimidine-2,4-dione, BAY 069, BAY069
• Empirische Formel (Hill-System): C₂₂H₁₄ClF₃N₂O₃
• CAS-Nummer: 2639638-67-6
• Molekulargewicht: 446.81
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD34789523
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• shipped in: wet ice
• storage temp.: −70°C

Beschreibung

Biochem/physiol Actions

BAY-069 is a non-cytotoxic (anti-proliferation IC50 >47 μM using 6 cell lines), potent and selective branched chain amino acid (BCAA) transaminase (BCAT) inhibitor (BCAT1/2 IC50 = 27/130 nM; glutamic-oxaloacetic transaminase GOT1/2 IC50 >50 μM) with good selectivity over a panel of 30 kinases, 30 proteases and 77 other targets. BAY-069 upregulates BCAAs in high BCAT1-expressing U-87 MG and high BCAT2-expressing MDA-MB-231 (IC50 = 358 and 874 nM, respectively) with good pharmacokinetics and oral bioavailability in rats in vivo.

Orally available, non-cytotoxic, potent and selective branched chain amino acid (BCAA) transaminase 1/2 (BCAT1 & BCAT2) inhibitor.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable